Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

XOMA and Takeda expand antibody collaboration
April 2007
SHARING OPTIONS:

BERKELEY, Calif.XOMA Ltd. and Osaka, Japan-based Takeda Pharmaceutical Co. recently amended an existing agreement to increase the number of potential therapeutic antibody programs under their collaboration. With this expansion, XOMA estimates the aggregate upfront, R&D funding, milestone and other payments could exceed $230 million, before royalties, over the life of the agreement. Since entering the original agreement in November, XOMA has received or is due approximately $8 million in various collaboration-related payments.
 
"XOMA is well-positioned to capitalize on the growing demand for monoclonal antibody solutions and this expanded agreement validates our strengths in translating targets into therapeutic product candidates and advancing their development thereafter," says John L. Castello, chairman, president and CEO of XOMA
 
"Takeda has an extensive collection of cancer-related disease targets that hold promise for therapeutic intervention using monoclonal antibodies," notes Dr. Shigenori Ohkawa, general manager of Takeda's pharmaceutical research division. "By expanding our collaboration with XOMA, we are able to accelerate our antibody drug discovery and development efforts in oncology."

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.